Drug intelligence / Profile preview

KT18

Development stage: Preclinical
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

KT18 is a T-cell receptor (TCR) clone developed as a T-cell receptor-based therapeutic. It is designed to specifically recognize and eliminate KRAS G12V-mutant tumor cells. This TCR demonstrates superior functional avidity and, importantly, lacks off-target activity against the endogenously expressed RAB7B self-peptide, a critical safety concern for other KRAS G12V-specific TCRs. Preclinical validation in multiple xenograft models has shown that KT18 TCR-T cells mediate potent and significant tumor regression. It is being developed for clinical use against KRAS G12V-driven solid tumors.

Targets

KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)HLA-A*11

Beyond the preview

Go deeper on KT18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT18.

Explore the full profile